Details of the Drug Reposition

General Information of This Drug (ID: DM0VQN3)

Drug Name
Ofloxacin   DM0VQN3
Synonyms
Bactocin; DEXTROFLOXACINE; Danoflox; Effexin; Exocin; Exocine; Flobacin; Flodemex; Flotavid; Flovid; Floxal; Floxil; Floxin; Floxstat; Fugacin; Inoflox; Kinflocin; Kinoxacin; Liflox; Loxinter; Marfloxacin; Medofloxine; Mergexin; Novecin; Nufafloqo; OFLX; OFX; Obide; Occidal; Ocuflox; Ofcin; Oflin; Oflocee; Oflocet; Oflocin; Oflodal; Oflodex; Oflodura; Oflox; Ofloxacina; Ofloxacine; Ofloxacino; Ofloxacinum; Ofloxin; Ofus; Onexacin; Operan; Orocin; Otonil; Oxaldin; Pharflox; Praxin; Puiritol; Qinolon; Qipro; Quinolon; Quotavil; Rilox; Sinflo; Tabrin; Taravid; Tariflox; Tarivid; Telbit; Tructum; Viotisone; Visiren; XED; Zanocin; Floxin otic; Ofloxacin Otic; Ofloxacina [DCIT]; Ofloxacine [French]; Ofloxacino [Spanish]; Ofloxacinum [Latin]; Uro Tarivid; DL 8280; HOE 280; O 8757; ORF 18489; PT 01; DL-8280; FLOXIN IN DEXTROSE 5%; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Floxin Otic (TN); HOE-280; Hoe-280; Marfloxacin (TN); O-Flox; ORF-28489; Ocuflox (TN); Ru-43280; WP-0405; Ofloxacin (JP15/USP/INN); Ofloxacin [USAN:BAN:INN:JAN]; Ofloxacin, (S)-Isomer; DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; (+/-)-Floxin; (-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
20 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Streptococcal pneumonia DIS2EKMJ N.A. Approved [1]
Staphylococcus aureus infection DISK6PTH N.A. Approved [1]
Staphylococcal pneumonia DIS28ZSZ N.A. Approved [1]
Pyelonephritis DISAOX93 N.A. Approved [1]
Prostatitis DISL8OGN N.A. Approved [1]
Mycoplasma pneumoniae pneumonia DIS1AW2Z N.A. Approved [1]
Malignant otitis externa caused by Pseudomonas aeruginosa DIS5C8KP N.A. Approved [1]
Latent tuberculosis infection DIS6R1EH N.A. Approved [1]
Chronic tubotympanic suppurative otitis media DIS7R96F N.A. Approved [1]
Chancroid DISMVLOF N.A. Approved [1]
Acute maxillary sinusitis DISEUB5R N.A. Approved [1]
Acute gonococcal cervicitis DIS4LKDT N.A. Approved [1]
Bacterial infection DIS5QJ9S 1A00-1C4Z Approved [2]
Bacillary dysentery DISFZHKN 1A02 Approved [1]
Anthrax DISFPT78 1B97 Approved [1]
Bronchitis DISBM6EQ CA20 Approved [1]
Pneumonia DIS8EF3M CA40 Approved [1]
Cystitis DIS2D4B9 GC00 Approved [1]
Urinary tract infection DISMT6UV GC08 Approved [1]
Traveler's diarrhea DIS4R0UE ME05.1 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 20 Indications(s)
2 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute gonococcal endometritis DISZ8BW7 N.A. Withdrawn [3]
Peritonsillar abscess DISZZXTZ N.A. Withdrawn [4]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Otitis externa DISYCORK AA00-AA13 Discontinued in Phase 3 [5]
------------------------------------------------------------------------------------
4 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bacterial conjunctivitis DIST79FU N.A. Discontinued in Phase 2 [6]
Rhinoscleroma DISNSWVK N.A. Discontinued in Phase 2 [7]
Escherichia coli infection DISPP65M 1A03 Discontinued in Phase 2 [8]
Gonorrhea DISQ5AO6 1A7Z Discontinued in Phase 2 [9]
------------------------------------------------------------------------------------
3 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bacterial urinary tract infection DISNNJTF N.A. Discontinued in Phase 1 [10]
Typhoid fever DISP3NHR 1A07 Discontinued in Phase 1 [11]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Discontinued in Phase 1 [12]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pneumonia caused by chlamydia DISX7CHR N.A. Investigative [1]
------------------------------------------------------------------------------------

References

1 Ofloxacin FDA Label
2 Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.
3 "The Evaluation of Stimulant Withdrawal"
4 Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
5 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
6 VELCADE,Rituximab,Cyclophosphamide and Decadron
7 Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma
8 Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
9 S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer
10 Safety Assessment of Atomoxetine With MA IV Administration
11 ClinicalTrials.gov (NCT00096005) Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
12 Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes